Limits...
Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience.

Mesti T, Moltara ME, Boc M, Rebersek M, Ocvirk J - Radiol Oncol (2015)

Bottom Line: There were 16 cases of hematopoietic toxicity grade (G) 1-2.Non-hematopoietic toxicity was present in 14 cases, all G1-2, except for one patient with proteinuria G3.No grade 4 toxicities, no thromboembolic event and no intracranial hemorrhage were observed.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.

ABSTRACT

Background: Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial.

Patients and methods: The medical documentation of 19 adult patients with recurrent malignant gliomas was retrospectively reviewed. All patients received bevacizumab (10 mg/kg) and irinotecan (340 mg/m(2) or 125 mg/m(2)) every two weeks. Patient clinical characteristics, drug toxicities, response rate, progression free survival (PFS) and overall survival (OS) were evaluated.

Results: Between August 2008 and November 2011, 19 patients with recurrent malignant gliomas (median age 44.7, male 73.7%, WHO performance status 0-2) were treated with bevacizumab/irinotecan regimen. Thirteen patients had glioblastoma, 5 anaplastic astrocytoma and 1 anaplastic oligoastrocytoma. With exception of one patient, all patients had initially a standard therapy with primary resection followed by postoperative chemoradiotherapy. Radiological response was confirmed after 3 months in 9 patients (1 complete response, 8 partial responses), seven patients had stable disease and three patients have progressed. The median PFS was 6.8 months (95% confidence interval [CI]: 5.3-8.3) with six-month PFS rate 52.6%. The median OS was 7.7 months (95% CI: 6.6-8.7), while six-month and twelve-month survival rates were 68.4% and 31.6%, respectively. There were 16 cases of hematopoietic toxicity grade (G) 1-2. Non-hematopoietic toxicity was present in 14 cases, all G1-2, except for one patient with proteinuria G3. No grade 4 toxicities, no thromboembolic event and no intracranial hemorrhage were observed.

Conclusions: In recurrent malignant gliomas combination of bevacizumab and irinotecan might be an active regimen with acceptable toxicity.

No MeSH data available.


Related in: MedlinePlus

The median overall survival (OS).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4362611&req=5

f2-rado-49-01-80: The median overall survival (OS).

Mentions: The median PFS was 6.8 months (95% confidence interval [CI]: 5.3–8.3) (Figure 1) and the estimated six-month and twelve-month- PFS rates were 52.6% and 15.8%, respectively. The median OS was 7.7 months (95% CI: 6.6–8.7) (Figure 2), while the six-month and twelve-month survival rates were 68.4% and 31.6%, respectively.


Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience.

Mesti T, Moltara ME, Boc M, Rebersek M, Ocvirk J - Radiol Oncol (2015)

The median overall survival (OS).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4362611&req=5

f2-rado-49-01-80: The median overall survival (OS).
Mentions: The median PFS was 6.8 months (95% confidence interval [CI]: 5.3–8.3) (Figure 1) and the estimated six-month and twelve-month- PFS rates were 52.6% and 15.8%, respectively. The median OS was 7.7 months (95% CI: 6.6–8.7) (Figure 2), while the six-month and twelve-month survival rates were 68.4% and 31.6%, respectively.

Bottom Line: There were 16 cases of hematopoietic toxicity grade (G) 1-2.Non-hematopoietic toxicity was present in 14 cases, all G1-2, except for one patient with proteinuria G3.No grade 4 toxicities, no thromboembolic event and no intracranial hemorrhage were observed.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.

ABSTRACT

Background: Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial.

Patients and methods: The medical documentation of 19 adult patients with recurrent malignant gliomas was retrospectively reviewed. All patients received bevacizumab (10 mg/kg) and irinotecan (340 mg/m(2) or 125 mg/m(2)) every two weeks. Patient clinical characteristics, drug toxicities, response rate, progression free survival (PFS) and overall survival (OS) were evaluated.

Results: Between August 2008 and November 2011, 19 patients with recurrent malignant gliomas (median age 44.7, male 73.7%, WHO performance status 0-2) were treated with bevacizumab/irinotecan regimen. Thirteen patients had glioblastoma, 5 anaplastic astrocytoma and 1 anaplastic oligoastrocytoma. With exception of one patient, all patients had initially a standard therapy with primary resection followed by postoperative chemoradiotherapy. Radiological response was confirmed after 3 months in 9 patients (1 complete response, 8 partial responses), seven patients had stable disease and three patients have progressed. The median PFS was 6.8 months (95% confidence interval [CI]: 5.3-8.3) with six-month PFS rate 52.6%. The median OS was 7.7 months (95% CI: 6.6-8.7), while six-month and twelve-month survival rates were 68.4% and 31.6%, respectively. There were 16 cases of hematopoietic toxicity grade (G) 1-2. Non-hematopoietic toxicity was present in 14 cases, all G1-2, except for one patient with proteinuria G3. No grade 4 toxicities, no thromboembolic event and no intracranial hemorrhage were observed.

Conclusions: In recurrent malignant gliomas combination of bevacizumab and irinotecan might be an active regimen with acceptable toxicity.

No MeSH data available.


Related in: MedlinePlus